Wockhardt Q1 FY27: Consolidated PAT swings to ₹107 Cr from ₹108 Cr loss, revenue up 26%

Wockhardt's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 26% YoY to ₹929 Cr from ₹738 Cr, while consolidated PAT turned around to a ₹107 Cr profit from a ₹108 Cr net loss a year ago. Sequentially the print is softer — revenue is down 3.7% from ₹965 Cr and PAT down 34.8% from ₹164 Cr in Q4 FY26 — consistent with typical post-year-end normalisation rather than any deterioration in the underlying business, since the YoY comparison is the primary read here. The swing is only partly a base-effect story. Total expenses grew just 9.6% YoY (₹844 Cr vs ₹770 Cr) against 26% revenue growth, so operating leverage did the bulk of the work — profit before exceptional items and tax improved to ₹116 Cr from a ₹12 Cr loss, a ₹128 Cr swing. Layered on top, the year-ago quarter carried a ₹97 Cr exceptional charge (nature undisclosed in this filing) that is absent this quarter, and the exchange-fluctuation line moved from a ₹29 Cr loss to a ₹4 Cr gain, a further ~₹33 Cr favourable swing. Stripping out the ₹97 Cr exceptional charge, the year-ago quarter's underlying loss was closer to ₹11 Cr rather than ₹108 Cr — so while the headline move is a clean turnaround (loss to profit) both on a reported and adjusted basis, roughly ₹95 Cr of the ₹225 Cr pre-tax swing is core operating recovery rather than one-off reversal. Consolidated NPM recovered to 11.5% from -14.25% YoY, though it is down from 16.24% in the seasonally stronger Q4 print. Standalone (secondary) tells a similar story: PAT of ₹107 Cr on revenue of ₹561 Cr, up 55% and 36% YoY respectively, aided by a nil tax provision this quarter (against nil in the year-ago quarter too). No consensus PAT/revenue estimates for this specific quarter turned up in a web search, so the print cannot be graded against a formal Street number; our records and public sources also show no formal company guidance for Q1 FY27 revenue or profit specifically. What is on record is a broader, multi-quarter guidance thread tied to Wockhardt's FDA-approved novel antibiotic Zaynich (approved end-May 2026): management has flagged a minor negative bottom-line impact over the next 12-18 months as pre-launch and commercialisation costs scale, alongside open-ended global peak-sales guidance of $1.5-2 billion for the drug and a target to double the biosimilar business within 24-36 months of June 2026. This quarter's margin recovery does not yet show that anticipated pressure — it is early days for Zaynich's commercial ramp, so the guidance should be read as forward, not yet due. Alongside the results, the company launched an "Antibiotic Academy" aimed at antimicrobial-resistance (AMR) education — management framed it around the need for "a science-based platform that fosters constructive dialogue on antimicrobial resistance," tying directly to Zaynich's positioning as a new-generation antibiotic; this is a brand/thought-leadership move rather than a financial driver and the numbers show no immediate P&L linkage to it. The board also confirmed no deviation in utilisation of prior QIP proceeds, a routine compliance disclosure with no bearing on this quarter's operating performance.